Business Wire11.01.18
Minnetronix Neuro, a division of Minnetronix Medical Inc., announced the completion of its first sponsored, multicenter study of Neurapheresis Therapy, the PILLAR trial. Spiros Blackburn, M.D., a neurosurgeon specializing in cerebrovascular and skull base surgery at Memorial Hermann in Houston, Texas, served as principal investigator for the lead enrolling site in the study.
The PILLAR study evaluated the safety, tolerability, and feasibility of Neurapheresis Therapy in patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). This new therapy is designed to facilitate the removal of targeted contaminants in the cerebral spinal fluid (CSF). In the case of an aSAH event, Neurapheresis Therapy targets removal of blood and blood byproducts remaining in the CSF following aneurysm securement with the goal of minimizing the inflammatory cascade caused by their presence.
“There is a significant unmet need for effective treatment options for subarachnoid hemorrhage patients and I am really encouraged by the therapy’s potential to improve patient outcomes,” said Christa Swisher, M.D., neurointensivist and site principal investigator for the study at Duke Health.
Neurapheresis Therapy is a platform technology in a portfolio of proprietary solutions being developed by Minnetronix Neuro for the Neuro intensive care unit (ICU). During this minimally invasive process, a dual lumen catheter is placed in the lumbar spine, and contaminated CSF is actively filtered to rapidly remove blood and blood breakdown byproducts. Clean CSF is simultaneously returned to the patient. Neurapheresis Therapy is considered a breakthrough treatment option for aSAH patients, with the potential to significantly advance the current standard of care, improve outcomes for patients and minimize the impact of aSAH on the healthcare system. Neurapheresis Therapy is an investigational device, limited by federal law to investigational use.
Minnetronix Neuro, a division of Minnetronix Medical, is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients in the Neuro ICU. The company is focused on delivering cost-effective solutions for physicians and patients to advance treatment options and improve outcomes.
The PILLAR study evaluated the safety, tolerability, and feasibility of Neurapheresis Therapy in patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). This new therapy is designed to facilitate the removal of targeted contaminants in the cerebral spinal fluid (CSF). In the case of an aSAH event, Neurapheresis Therapy targets removal of blood and blood byproducts remaining in the CSF following aneurysm securement with the goal of minimizing the inflammatory cascade caused by their presence.
“There is a significant unmet need for effective treatment options for subarachnoid hemorrhage patients and I am really encouraged by the therapy’s potential to improve patient outcomes,” said Christa Swisher, M.D., neurointensivist and site principal investigator for the study at Duke Health.
Neurapheresis Therapy is a platform technology in a portfolio of proprietary solutions being developed by Minnetronix Neuro for the Neuro intensive care unit (ICU). During this minimally invasive process, a dual lumen catheter is placed in the lumbar spine, and contaminated CSF is actively filtered to rapidly remove blood and blood breakdown byproducts. Clean CSF is simultaneously returned to the patient. Neurapheresis Therapy is considered a breakthrough treatment option for aSAH patients, with the potential to significantly advance the current standard of care, improve outcomes for patients and minimize the impact of aSAH on the healthcare system. Neurapheresis Therapy is an investigational device, limited by federal law to investigational use.
Minnetronix Neuro, a division of Minnetronix Medical, is developing a portfolio of solutions designed to prevent secondary injury and enhance healing for patients in the Neuro ICU. The company is focused on delivering cost-effective solutions for physicians and patients to advance treatment options and improve outcomes.
